Moreover, pharmacological blockade of p300/CBP significantly reduced the diabetes-associated inflammatory response in the kidney, as demonstrated by the knock-down effects on MCP-1, TNFα, NOS2, ICAM-1, VCAM-1, and E-selectin transcript levels. Here, CCL2 is linked to diabetes mellitus.